ERBB2 and breast carcinoma: Collectively, our findings identify FASN as a novel mediator of endocrine resistance in luminal B-like, ER+/HER2+ breast carcinomas that might be exploited as potential therapeutic target and biomarker of response to tamoxifen in the clinic.